Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis
NCT01505088
Completed
The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery System (EGDS) compared to prednisolone acetate ophthalmic suspension (1%) in patients with non-infectious anterior segment uveitis.
Gender:
ALL
Ages:
Between 12 years and 85 years
Trial Updated:
03/28/2013
Locations: Austin Retina Associates, Austin, Texas +2 locations
Conditions: Anterior Uveitis
Register for Updates
Topical Treatment of Acute Otitis Media Through Tympanostomy Tubes (AOMT) and Its Effect on Microbial Flora
NCT01027494
Completed
The purpose of this observational study was to evaluate the effects of a topical fluoroquinolone (antibiotic) instilled into the otic (ear) canal to treat Acute Otitis Media through Tympanostomy Tubes (AOMT) on selected bacterial species on the skin near the ear, in the nose, and in the throat.
Gender:
ALL
Ages:
Between 6 months and 4 years
Trial Updated:
03/14/2013
Locations: Contact Alcon Call Center for Trial Locations, Fort Worth, Texas
Conditions: Acute Otitis Media
Register for Updates
Retrospective Study in Patients Receiving Two or More OZURDEX® Injections for Retinal Vein Occlusion (RVO)
NCT01411696
Completed
This is a retrospective data collection study to evaluate the efficacy, safety, and re-injection interval of OZURDEX® in the treatment of macular edema due to RVO. Following informed consent, there were no patient study visits. All data was collected via chart review.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2013
Locations: Not set, San Antonio, Texas
Conditions: Retinal Vein Occlusion, Macular Edema
Register for Updates
Palonosetron in Sarcoma Patients Receiving Chemotherapy With Adriamycin and Ifosfamide (AI)
NCT00410488
Completed
The goal of this clinical research study is to compare 2 treatment schedules of Aloxi (palonosetron) in patients with sarcoma who are receiving chemotherapy with adriamycin and ifosfamide. The safety of the drug and schedules will be studied. The effect of palonosetron on patients' quality of life (QOL) will also be studied.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/19/2013
Locations: UT MD Anderson Cancer Center, Houston, Texas
Conditions: Sarcoma, Nausea, Vomiting
Register for Updates
Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia
NCT00002704
Completed
Phase II trial to study the effectiveness of radiation therapy following chemotherapy in treating children with CNS relapse from acute lymphoblastic leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with radiation therapy may kill more cancer cells.
Gender:
ALL
Ages:
20 years and below
Trial Updated:
01/31/2013
Locations: Medical City Dallas Hospital, Dallas, Texas +5 locations
Conditions: Leukemia
Register for Updates
Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma
NCT00050440
Completed
The purpose of this is to test the safety and effectiveness of an investigational chemotherapy agent in patients with persistent or recurrent endometrial cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/07/2013
Locations: Not set, Dallas, Texas
Conditions: Endometrial Neoplasms, Uterine Neoplasms, Genital Neoplasms, Female Urogenital Neoplasms
Register for Updates
A Phase II Study of Moxidex Ophthalmic Solution for Treatment of Marginal Corneal Infiltrates
NCT00579020
Terminated
The purpose of the study is to determine whether Moxidex ophthalmic solution is safe and effective in treating marginal corneal infiltrates.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
12/03/2012
Locations: Contact Alcon Call Center at 1-888-451-3937, Fort Worth, Texas
Conditions: Corneal Infiltrates
Register for Updates
Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia
NCT00136084
Completed
The purpose of this study is to compare the effectiveness of two multi-agent chemotherapy regimens using different dosages of cytarabine to eliminate all detectable leukemia.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
11/02/2012
Locations: Cook Children's Medical Center, Fort Worth, Texas +2 locations
Conditions: Leukemia, Myelocytic, Acute
Register for Updates
Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting
NCT00366834
Completed
This is a Phase III trial designed to demonstrate that casopitant (GW679769) plus dexamethasone and ondansetron is more effective in the prevention of vomiting than dexamethasone and ondansetron alone following the administration of moderately emetogenic chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/06/2012
Locations: GSK Investigational Site, Corpus Christi, Texas +3 locations
Conditions: Vomiting, Nausea, Nausea and Vomiting, Chemotherapy-Induced
Register for Updates
Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)
NCT00775411
Completed
The study will evaluate the safety and efficacy of the intravitreal dexamethasone implant as adjunctive therapy to Anti-VEGF treatment in the study eye of treatment naïve subjects with choroidal neovascularization secondary to age-related macular degeneration. Subjects will be followed for 26 weeks.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
08/01/2012
Locations: Not set, San Antonio, Texas
Conditions: Choroidal Neovascularization, Age-Related Maculopathy
Register for Updates
Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration
NCT01122511
Terminated
This study will evaluate the safety and efficacy of dexamethasone (OZURDEX®) as adjunctive therapy to ranibizumab (LUCENTIS®) compared with ranibizumab alone in the treatment of patients with choroidal neovascularization secondary to age-related macular degeneration
Gender:
ALL
Ages:
50 years and above
Trial Updated:
08/01/2012
Locations: Not set, Abilene, Texas
Conditions: Subfoveal Choroidal Neovascularization, Age-Related Maculopathy
Register for Updates
Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis
NCT01033825
Completed
To demonstrate the effects of ciclesonide applied as a nasal aerosol and ciclesonide aqueous (AQ) nasal spray on hypothalamic-pituitary-adrenal axis.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/17/2012
Locations: Central Texas Health Research, New Braunfels, Texas +1 locations
Conditions: Perennial Allergic Rhinitis
Register for Updates